Facebook
Twitter
Telegram
Report an ErrorZosano Pharma Corporation Balance Sheet 2011-2024 | ZSAN
Annual Balance Sheet Zosano Pharma Corporation
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-6.36 M | -33.1 M | 919 K | -4.66 M | -4.96 M | -2.46 M | 8.62 M | 20.8 M | 7.4 M | 4.05 M | - |
Long Term Debt |
3.08 M | 812 K | 6.1 M | 4.48 M | - | 6.55 M | 11.9 M | 13.3 M | 9.71 M | 9.03 M | - |
Long Term Debt Current |
1.61 M | 1.38 M | 1.14 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | 4.49 M | 12 M | 5.78 M | 495 K | 6.6 M | 12 M | 13.4 M | 10.1 M | 9.63 M | - |
Total Current Liabilities |
11.1 M | 14.5 M | 16.2 M | 11.3 M | 10.5 M | 9.82 M | 6.88 M | - | - | - | - |
Total Liabilities |
15.4 M | 24.5 M | 28.3 M | 17.1 M | 11 M | 16.4 M | 18.8 M | 26.7 M | 21.6 M | 13.6 M | - |
Deferred Revenue |
26 K | - | - | - | - | - | - | 170 K | 1.12 M | 3.38 M | - |
Retained Earnings |
-362 M | -332 M | -299 M | -261 M | -226 M | -197 M | -167 M | -138 M | -124 M | -119 M | - |
Total Assets |
48.4 M | 72 M | 37.7 M | 35.8 M | 18 M | 20.9 M | 45.3 M | 13.3 M | 22.1 M | 19.6 M | - |
Cash and Cash Equivalents |
11 M | 35.3 M | 6.32 M | 9.14 M | 11.7 M | 15 M | 6.65 M | 1.21 M | - | - | - |
Book Value |
33 M | 47.5 M | 9.39 M | 18.7 M | 7.05 M | 4.48 M | 26.5 M | -13.4 M | 477 K | 6.02 M | - |
Total Shareholders Equity |
33 M | 47.5 M | 9.39 M | 18.7 M | 7.05 M | 4.48 M | 26.5 M | -13.4 M | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Zosano Pharma Corporation
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | 2.66 M | - | - | - | 204 K | 812 K | 1.42 M | 888 K | 812 K | - | - | - | 30 K | - | - | 3.6 M | - | 6.69 M | 8.18 M | 9.63 M | 11.2 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | 12.4 M | 15.4 M | 16.8 M | 17.8 M | 22.6 M | 24.5 M | 25.2 M | 29.2 M | 31.4 M | 28.3 M | 28.3 M | 28.3 M | 28.3 M | 17.1 M | 17.1 M | 17.1 M | 17.1 M | 11 M | 11 M | 11 M | 11 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 18.8 M | 18.8 M | 18.8 M | 18.8 M | 26.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | 26 K | 47 K | 226 K | 47 K | - | - | - | - | - | - | - | - | - | - | 62 K | - | - | - | - | - | - | - | - | - | - | - | - | 68 K | 170 K | 170 K | 170 K | 170 K | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | - | - | -396 M | -362 M | -355 M | -346 M | -340 M | -332 M | -324 M | -315 M | -308 M | -299 M | -299 M | -299 M | -299 M | -261 M | -261 M | -261 M | -261 M | -226 M | -226 M | -226 M | -226 M | -197 M | -197 M | -197 M | -197 M | -167 M | -167 M | -167 M | -167 M | -138 M | -138 M | -138 M | -138 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
- | - | - | 26.4 M | 48.4 M | 55 M | 60.8 M | 65.7 M | 72 M | 80.5 M | 47.7 M | 55.3 M | 37.7 M | 37.7 M | 37.7 M | 37.7 M | 35.8 M | 35.8 M | 35.8 M | 35.8 M | 18 M | 18 M | 18 M | 18 M | 20.9 M | 20.9 M | 20.9 M | 20.9 M | 45.3 M | 45.3 M | 45.3 M | 45.3 M | 13.3 M | 13.3 M | 13.3 M | 13.3 M | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
- | - | - | 13.5 M | 11 M | 17.1 M | 22.1 M | 26.9 M | 35.3 M | 35.3 M | 35.3 M | 35.3 M | 6.32 M | 6.32 M | 6.32 M | 6.32 M | 9.14 M | 9.14 M | 9.14 M | 9.14 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 15 M | 15 M | 15 M | 15 M | 6.65 M | 6.65 M | 6.65 M | 6.65 M | 1.21 M | 1.21 M | 1.21 M | 1.21 M | 5.91 M | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
- | - | - | 14.1 M | 33 M | 38.2 M | 43.1 M | 43.2 M | 47.5 M | 55.2 M | 18.5 M | 24 M | 9.39 M | 9.39 M | 9.39 M | 9.39 M | 18.7 M | 18.7 M | 18.7 M | 18.7 M | 7.05 M | 7.05 M | 7.05 M | 7.05 M | 4.48 M | 4.48 M | 4.48 M | 4.48 M | 26.5 M | 26.5 M | 26.5 M | 26.5 M | -13.4 M | 13.3 M | 13.3 M | 13.3 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
- | - | - | 14.1 M | 33 M | 38.2 M | 43.1 M | 43.2 M | 47.5 M | 55.2 M | 47.5 M | 24 M | 9.39 M | 10.4 M | 9.39 M | 9.39 M | 18.7 M | 18.7 M | 18.7 M | 18.7 M | 7.05 M | 7.05 M | 7.05 M | 7.05 M | 4.48 M | 4.48 M | 4.48 M | 4.48 M | 26.5 M | 26.5 M | 26.5 M | 26.5 M | -13.4 M | -13.4 M | -13.4 M | -13.4 M | 477 K | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency